Abstract
Severe radiation-induced lymphopenia in patients undergoing chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC) is associated with detrimental survival outcomes and decreased efficacy of subsequent immunotherapy. This impact provides a strong incentive to identify patients at high risk who could benefit from lymphopenia-mitigating strategies. At The Christie, a prediction model for grade ≥3 lymphopenia was developed in lung cancer patients. At MDACC, a model for grade 4 lymphopenia was developed in esophageal cancer patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.